康诺亚-B司普奇拜单抗鼻科先拔头筹,密集BD出海尽显管线价值(简体版)

第一上海
27 Mar

2024年全年业绩回顾公司2024全年实现收入4.3亿元,其中商业化收入4300万元,BD收入3.9亿元。全年研发费用同比增加23%,共约7.4亿元。销售费用1.1亿。截止2025年2月,公司已建立了超300人的商业化团队,销售网络已覆盖226个城市,超1100家医院。由于研发投入的持续扩大和商业化能力建设,公司全年亏损同比扩大44%,达5.1亿元。截止2024年末,公司持有现金及银行理财产品合计...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10